According to Charles River Laboratories 's latest financial reports the company's current earnings (TTM) are $0.58 B. In 2022 the company made an earning of $0.62 B an increase over its 2021 earnings that were of $0.48 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | $0.58 B | -6.69% |
2022 | $0.62 B | 29.6% |
2021 | $0.48 B | 7.51% |
2020 | $0.44 B | 47.04% |
2019 | $0.30 B | 7.95% |
2018 | $0.28 B | -5.14% |
2017 | $0.29 B | 33.21% |
2016 | $0.22 B | 14.07% |
2015 | $0.19 B | 10.04% |
2014 | $0.17 B | 28.39% |
2013 | $0.13 B | 6.61% |
2012 | $0.12 B | -2.2% |
2011 | $0.13 B | -140.16% |
2010 | -$0.34 B | -321.56% |
2009 | $0.14 B | -131.92% |
2008 | -$0.47 B | -314.85% |
2007 | $0.21 B | 23.14% |
2006 | $0.17 B | 10.82% |
2005 | $0.15 B | 4.46% |
2004 | $0.15 B | 15% |
2003 | $0.13 B | 15.93% |
2002 | $0.11 B | 64.66% |
2001 | $69.47 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Thermo Fisher Scientific TMO | $6.29 B | 983.46% | ๐บ๐ธ USA |
SCYNEXIS SCYX | $70.3 M | -87.90% | ๐บ๐ธ USA |
Repligen
RGEN | $36.72 M | -93.68% | ๐บ๐ธ USA |